Susan Emeigh Hart
About Susan Emeigh Hart
Susan Emeigh Hart Education and Certifications
Susan Emeigh Hart holds a V.M.D. from the University of Pennsylvania School of Veterinary Medicine and a Ph.D. from The University of Connecticut. She earned her B.S. in Animal Science from The Pennsylvania State University. She is board certified in both Anatomic and Clinical Pathology through the American College of Veterinary Pathologists and in General Toxicology through the American Board of Toxicology. Additionally, she is a Eurotox Registered Toxicologist through the UK Registry of Toxicology.
Susan Emeigh Hart Career Background
Susan Emeigh Hart has over 25 years of experience in preclinical drug development. She currently serves as Vice President, Non-Clinical Safety. Previously, she was Vice President, Preclinical Development at Intrexon Corporation and Senior Director, Non-Clinical Development at Auxilium Pharmaceuticals. Her career also includes roles such as Senior Director, Safety Assessment at Genaera Corporation, and various positions at pharmaceutical companies including AstraZeneca, Bristol-Myers Squibb, DuPont Pharmaceuticals, and Pfizer.
Susan Emeigh Hart Role and Expertise
In her current role as Vice President, Non-Clinical Safety, Susan Emeigh Hart manages non-clinical drug development programs and regulatory submissions (IND through NDA/BLA) for small molecules and monoclonal antibodies. Her expertise extends to unusual biopharmaceuticals, including peptides, aminosterols, oligonucleotides, non-antibody, non-recombinant proteins, and gene therapy products. She has experience across diverse therapeutic areas such as cardiovascular/metabolic diseases, anti-infectives, oncology, CNS, rheumatology/orthopedics, and ophthalmology.
Susan Emeigh Hart Academic Contributions
Susan Emeigh Hart serves as an Adjunct Associate Professor (Pathology) at the University of Pennsylvania School of Veterinary Medicine. In this role, she contributes to the academic community through teaching and research, sharing her extensive knowledge and experience in pathological and toxicological studies with the next generation of veterinary medicine professionals.
Susan Emeigh Hart Professional Experience
Susan Emeigh Hart’s professional experience includes her role as Director of Experimental Pathology in the Nonclinical Drug Safety (US) department at Boehringer Ingelheim. Her comprehensive background in safety assessment and preclinical development has enabled her to lead successful drug development programs in various therapeutic areas and manage regulatory submissions from investigational new drugs (IND) to new drug applications (NDA) and biologics license applications (BLA).